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Abstract Diffuse large B-cell lymphoma (DLBCL) with a
germinal center B-cell (GCB) phenotype is believed to
confer a better prognosis than DLBCL with an activated
B-cell (ABC) phenotype. Previous studies have suggested
that nuclear factor-κB( N F - κB) activation plays an impor-
tant role in the ABC subtype of DLBCL, whereas c-REL
amplification is associated with the GCB subtype. Using
immunohistochemical techniques, we examined 68 new-
ly diagnosed de novo DLBCL cases (median follow-up
44 months, range 1 to 142 months) for the expression of
c-REL, BCL-6, CD10, and MUM1/IRF4. Forty-four (65%)
cases demonstrated positive c-REL nuclear expression. In
this cohort of patients, the GCB phenotype was associated
with a better overall survival (OS) than the non-GCB
phenotype (Kaplan–Meier survival (KMS) analysis, p=
0.016, Breslow–Gehan–Wilcoxon test). In general, c-REL
nuclear expression did not correlate with GCB vs. non-
GCB phenotype, International Prognostic Index score, or
OS. However, cases with a GCB phenotype and negative
nuclear c-REL demonstrated better OS than cases with a
GCB phenotype and positive nuclear c-REL (KMS analysis,
p=0.045, Breslow–Gehan–Wilcoxon test), whereas in cases
with non-GCB phenotype, the expression of c-REL did not
significantly impact the prognosis. These results suggest that
c-REL nuclear expression may be a prognostic factor in
DLBCL and it may improve patient risk stratification in
combination with GCB/non-GCB phenotyping.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common subtype of non-Hodgkin’s lymphoma, and it
comprises approximately 30–40% of new lymphoma diagno-
ses in the USA [1, 2]. Recently, using expression microarray
technology, several studies have shown that DLBCL can be
divided into three subgroups based on gene expression
profiles. These include germinal center B-cell-like (GCB),
activated B-cell-like (ABC), and type 3 [3, 4]. Independent
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tional Prognostic Index (IPI) [5], patients with a gene
expression profile resembling a GCB type have significantly
better overall survival than those with an ABC type; the type
3 group also has a poor prognosis, but it represents a
heterogeneous category that is not yet well defined.
Immunohistochemistry (IHC), a technology that is more
widely available and economically feasible than expression
microarrays, has been attempted for classifying DLBCL into
GCB and non-GCB subgroups using different combinations
of CD10, BCL-6, MUM1, and/or CD138 [6–9]. The majority
of these studies have confirmed significantly better survival
for GCB group suggesting that IHC is an important tool to
validate the microarray findings in pathology practice [6–9].
The nuclear factor-κB (NF-κB) signaling pathway plays
an important role in regulating the survival of normal and
malignant B-cells by controlling the expression of multiple
cell death regulatory pathways [10, 11]. The recent develop-
ment of NF-κB inhibitors may make this pathway a potential
therapeutic target for lymphoma [12]. NF-κBt a r g e tg e n e s
can enhance cell survival by modulating TNFα signaling,
inhibiting FAS-mediated apoptosis, and limiting the activity
of BCL2 family members [11]. The role of NF-κBp a t h w a y s
in different subgroups of DLBCL has not been well
elucidated [12]. Although some studies suggest that consti-
tutive activation of NF-κB contributes to the sustained
oncogenicity of the ABC-like DLBCL [12–14], a recent
expert review encouraged cautious interpretation of this data
[12]. Studies have also suggested that c-REL amplification, a
subunit of the REL/NF-κB family, is more commonly
observed in GCB-type DLBCL than ABC-type DLBCL
[4]; however, c-REL amplification is not frequently associ-
ated with NF-κB activation (nuclear c-REL expression)
[10, 11, 15].
Activation of the NF-κB pathway in a B-cell lymphoma
can be preliminarily assessed by determining the nuclear
localization of NF-κB subunits such as c-REL [16–18]. In
the inactive status, NF-κB heterodimers (c-REL or REL
homolog A and NF-κB1) reside in the cytoplasm bound to
an inhibitor of kappa B signaling (I-κB) [11]. During NF-
κB activation, I-kappa kinase (I-κK) phosphorylates I-κB
resulting in the dissociation of the inhibitor from the
cytoplasmic NF-κB heterodimer. Thereafter, the freed
(activated) NF-κB heterodimer, including c-REL, trans-
locates to the nucleus where it induces the transcription of
NF-κB target genes [11].
Using c-REL nuclear expression by IHC as a surrogate
marker for NF-κB activation, studies have demonstrated
that primary mediastinal large B-cell lymphoma cases show
homogeneously strong c-REL nuclear staining, whereas the
c-REL staining pattern in other DLBCL is more variable
[16, 17, 19]. However, these studies have not attempted to
correlate c-REL expression with clinical parameters. The
main goal of the current study was to evaluate the impact of
c-REL expression and GCB status on the clinical outcome
in DLBCL patients using IHC.
Materials and methods
Case selection
DLBCL cases from 1992–2001 were retrospectively re-
trieved from the archives of the Department of Pathology at
the Medical College of Wisconsin and The Methodist
Hospital. Sixty-eight cases (44 cases from a tissue micro-
array with each case consisting of three 1.2-mm cores and
24 cases from whole tissue sections) of newly diagnosed de
novo DLBCLs with adequate clinical follow-up informa-
tion were included in the study. This cohort included 15
cases from a previous study [6]. Cases with a preceding
diagnosis of low-grade lymphoma or a history of having
received immunosuppressive therapy were excluded from
the study. This cohort of patients did not include DLBCL
cases occurring in the central nervous system (CNS) or
mediastinum, because primary DLBCL of the CNS and
primary mediastinal large B-cell lymphoma are considered
distinct clinicopathologic subgroups of DLBCL by WHO
classification [20]. A single case of DLBCL occurring in
bone in our file were excluded in this study since we could
not determine if this case represented primary lymphoma or
secondary involvement of lymphoma based on the clinical
information available. The pertinent clinical information for
each case was obtained by reviewing the tumor registry
records and/or patient medical charts. This study was
approved by the Institutional Review Boards of the
participating institutions.
Histopathology
All cases were reviewed to confirm that morphologic
characteristics fulfilled the criteria of DLBCL by the
WHO classification [20]. The H&E-stained sections of all
cases show a neoplasm of large B lymphoid cells with
nuclear size equal to or exceeding normal macrophage
nuclei or more than twice the size of a normal lymphocyte
that has a diffuse growth pattern.
Immunohistochemistry
Immunohistochemical staining was performed using anti-
bodies against c-REL and a panel of GC B-cell (CD10 and
BCL-6) and activation (MUM1/IRF4) markers as previously
published [6]. For c-REL staining, the slides were pre-
treated with Citrate (DAKO USA, Carpinteria, CA, USA)
for 30 min in a steamer. Primary rabbit anti-c-REL(AB-1)
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San Diego, CA, USA) was applied in DAKO diluent for
1 h. The slides were washed, and the Dual Envision Kit
(DAKO) was then applied for 30 min. After further
washing, immunoperoxidase staining was developed using
a diaminobenzidine chromogen kit (DAKO). CD10, BCL-
6, and MUM1/IRF4 staining were performed as previously
described [6].
Two hematopathologists (CVC and CCC) independently
reviewed each case and assigned a semiquantitative score
for the expression of each antigenic marker without the
knowledge of clinical information. Each case was evaluated
by visual estimation and recorded in 10% increments. Any
discrepancies were resolved by reviewing slides with a
multi-headed microscope to achieve consensus. Expression
of each marker was considered positive when >20% of
large neoplastic lymphocytes stained positively at the
appropriate subcellular locations (c-REL, BCL-6, and
MUM1/IRF4 with nuclear and/or cytoplasmic staining;
CD10 with membranous and/or cytoplamic staining). This
cutoff has been commonly used in previous studies
evaluating protein expression by IHC [21–23].
Statistical methods
Demographics were summarized using frequencies and
percentages for categorical variables and median and range
for continuous variables. Survival probabilities were calcu-
lated using the Kaplan–Meier analysis. All analyses were
done using SAS v 5.0.1.
Results
The cohort contained 36 females (53%) and 32 males
(47%), ranging in age from 16 to 88 years (mean 63 years).
The median follow-up was 43 months (range 0–142 months)
and the median follow-up among survivors was 66 months
(range 14–142 months). All patients received Cytoxan,
Doxorubicin, Vincristine, and Prednisone- (CHOP-) based
chemotherapy without Rituximab. We were able to abstract
IPI scores in 34 cases. Twenty-three had low IPI scores (≤2,
low risk and low-intermediate risk groups) and 11 had high
IPI scores (>3, high-intermediate risk and high risk groups).
Forty-four cases (65%) were positive for c-REL nuclear
expression. They showed moderate to strong nuclear and
cytoplasmic staining of 20% to 100% of the large neoplastic
lymphocytes (Fig. 1). The remaining 24 cases (35%) were
negative for c-REL expression. The majority of the c-REL
negative cases showed weak to moderate cytoplasmic
staining in large neoplastic lymphocytes with rare scattered
nuclei showing weak staining (Fig. 1). The frequencies of
expression for CD10, BCL-6, and MUM1 in the cases
Fig. 1 Representative photomicroghs of c-REL expression in DLBCL
(original magnification, ×400; immunohistochemical c-REL stain). a,
b Negative c-REL expression cases: Negative nuclear expression with
weak (a) and moderate (b) cytoplasmic expression, respectively. c
Case scored as positive c-REL showing both nuclear and cytoplasmic
staining; note small lymphocytes without nuclear or cytoplasmic
staining
22 J Hematopathol (2009) 2:20–26studied were as follows: 29 of 68 (43%), 50 of 68 (74%),
and 44 of 68 (65%; Table 1). The frequencies of antigen
expression were quite comparable between the cases using
tissue microarray and the cases using whole tissue section,
suggesting that there was no sampling bias using tissue
microarray. Based on these results, 24 cases (35%) were GCB
phenotype (CD10+ and/or BCL-6+, MUM1-), and 44 cases
(65%) were non-GCB phenotype (MUM1+, regardless of
CD10 and BCL-6 expression) using the classification scheme
by Chang et al. [6]. Using Hans’s classification methods [7],
34 cases (50%) were GCB phenotype (CD10+ or CD10-/
BCL6+/MUM1-) and 34 cases (50%) were non-GCB
phenotype (CD10-/BCL6- or CD10-/BCL6+/MUM1+).
Of note, there was no statistically significant difference
in the frequency of c-REL expression between the GCB
and non-GCB phenotype and other immunohistochemical
markers (CD10, BCL-6, or MUM1; Table 1). We further
evaluated multiple clinical parameters in relation to the
presence or absence of nuclear c-REL staining. No statisti-
cally significant correlation was observed between c-REL
nuclear expression and age, sex, extranodal sites, or IPI
(Table 2).
The GCB subgroup showed better overall survival (OS)
than the non-GCB subgroup (50% cumulative survival not
reach for GCB compared to 25–26 months for non-GCB,
Kaplan–Meier survival analysis, p=0.016, Breslow–Gehan–
Wilcoxon test, Fig. 2a), using Chang’s classification
scheme. The results were similar using Han’s scheme for
defining GC and non-GC status (data not shown). Using
onlyc-RELexpression,nocorrelationwithOSwasobserved
(Fig. 2b). The finding of no correlation with OS remained
the same when the data was analyzed using the 50%
cutoff as defined by Rodig et al. [16] for c-REL expression
(Fig. 2c). However, when combining c-REL nuclear expres-
sion with GCB vs. non-GCB phenotype as defined by Chang
et al., cases with a GCB phenotype and negative nuclear
c-REL had a better OS (only one out of nine patients died
at 96 months with a median follow-up of 72 months) than
cases with a GCB phenotype and positive nuclear c-REL
(six out of 16 patients died at a median of 18 months,
range1to46months,p=0.045, Breslow–Gehan–Wilcoxon
test (Fig. 2d)). When the GCB or non-GCB were defined
using Han’s classification, the similar trend of having a
better OS toward the group of patients with GCB phenotype
and negative nuclear c-REL was observed, but the difference
was not statistically significant (data not shown). Of noted,
there was no statistically difference of IPI among c-REL
positive or c-REL negative in the GCB phenotype sub-
groups (data not shown). Among the patients with non-GCB
phenotype, c-REL expression did not impact the OS (data
not shown).
Discussion
Using c-REL nuclear expression by immunohistochemistry
as a surrogate marker for NF-κB activation, our results
suggest that DLBCL with a GCB phenotype and negative
c-REL expression may have a better clinical outcome.
Furthermore, c-REL expression does not correlate with
either GCB or non-GCB phenotype or IPI score. Taken
together, c-REL expression in combination with GCB or
non-GCB phenotype evaluation may improve patient risk
Table 1 Correlation of nuclear c-REL expression with other
immunohistochemical markers in DLBCL
Immunohistochemical
markers
Parameter
(n)
Nuclear c-REL
expression
P value
Positive
(n=44)
Negative
(n=24)
CD10
Positive 29 20 9 0.5262
a
Negative 39 24 15
BCL6
Positive 50 30 20 0.1759
a
Negative 18 14 4
MUM1/IRF4
Positive 44 29 15 0.7786
a
Negative 24 15 9
GCB vs non-GCB phenotype
Non-GCB 44 29 15 0.7786
a
GCB 24 15 9
aChi Square
Table 2 Comparison of clinical features in patients with or without
positive nuclear c-REL Expression in DLBCL
Clinical
parameters
Parameter
(n)
Nuclear c-REL
expression
P value
Positive
(n=44)
Negative
(n=24)
Age
<60 23 15 8 0.9497
a
≥60 45 29 16
Sex
Male 32 19 13 0.3858
a
Female 36 25 11
Site
Nodal 37 21 16 0.1340
a
Extranodal 31 23 8
IPI
Low (0–2) 23 16 7 0.8499
a
High (3–5) 11 8 3
aChi Square
J Hematopathol (2009) 2:20–26 23stratification in DLBCL. The detailed mechanisms leading
to a better prognosis in the GCB subtype cases without c-
REL expression remain to be elucidated. One possible
mechanism would be increased susceptibility to chemo-
therapy imparted by a lack of NF-κB activation and its
resultant reduction in anti-apoptotic signals in the neoplas-
tic lymphocytes. Additionally, the observed decreased
OS among cases of GCB phenotypes with c-REL nuclear
expression suggests that the lymphoma cells, even with a
good prognostic GCB phenotype, may become resistant to
chemotherapeutic agents once the NF-κB pathway is
activated. Therefore, these cases may benefit from the
addition of an NF-κB inhibitor to the CHOP regimen.
However, in cases with the non-GCB phenotype, the c-REL
nuclear expression (NF-κB activation) does not correlate
with OS suggesting that other pathways leading to the more
aggressive clinical course may also be involved. It should
be noted that our findings are somewhat limited by the
nature of the retrospective study design since the treatment
and clinical evaluation may be relatively heterogeneous.
Our c-REL immunohistochemical staining results largely
correlate with those of previous studies. Others have also
reported that c-REL expression in DLBCL is heterogeneous
[16, 17, 19]. Furthermore, in agreement with previous
studies, we do not observe any correlation between clinical
parameters and c-REL nuclear expression [15]. However,
the frequency of c-REL nuclear expression appeared higher
in our study (65% vs. 18% to 44%, respectively) [16]. This
observation may be attributed to the use of different c-REL
antibody dilution, different staining methodologies, differ-
ent scoring criteria, and/or case selection bias. For example,
Rodig et al. used more stringent nuclear scoring criteria
with a cutoff of 50% of cells staining positive to be
considered positive [16]. These scoring criteria may have
underestimated the number of cases with activated NF-κB
signaling. When we used the same strict criteria to analyze
our data, the results of the statistical analysis remained
unchanged (Fig. 2c). Furthermore, we cannot compare our
OS data with these studies since the correlation between c-
REL nuclear expression and OS has not been attempted in
these studies.
Our results suggest that there is no correlation between c-
RELnuclearexpressionandGCBornon-GCBphenotypesby
immunohistochemical staining. This is in contrast to previous
experiments which reported that c-REL nuclear expres-
sion by immunofluorescence staining is more commonly
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Fig. 2 Overall survival (OS) curves by Kaplan–Meier survival
analysis. a OS curves using GCB versus non-GCB phenotypes. b
Negative c-REL versus positive c-REL expression by our criteria. c
Negative c-REL versus positive c-REL expression by Rodig’s criteria.
d Only cases classified as GCB phenotype: negative c-REL versus
positive c-REL expression
24 J Hematopathol (2009) 2:20–26observed in the ABC phenotype determined by expression
microarray analysis [15]. However, the difference described
by Houldsworth et al. was not statistically significant (c-REL
nuclear expression, 6/18 in GCB vs. 7/11 in non-GCB,
p=0.143, Fisher’s Exact). These differences may be
caused by the different c-REL detection methodologies
(immunofluorescence vs. IHC) or the different GCB/non-
GCB phenotype classification methodologies (expression
microarray vs. IHC). Further studies using IHC to study
the expression of NF-κB targeted gene activation are
ongoing in our laboratory. These experiments may provide
valuable insight into the role of NF-κBa c t i v a t i o ni n
the molecular pathogenesis of the different subtypes of
DLBCL.
In the current study, all the data were analyzed using two
published algorithms (one by our group and the other by
Han et al.) for classifying GCB vs. non-GCB phenotype of
DLBCL using IHC [6, 7]. Not surprisingly, two algorithms
in general agree with each other relatively well since the
only difference is that we consider any cases with MUM1
and CD10 expression as non-GCB while Han et al. consider
CD10 expression regardless of MUM1 status as GCB.
Nevertheless, the statistical significance of c-REL expres-
sion in GCB was observed using our classification algorithm
but not by Han et al. although the latter algorithm also
showed the similar trend. It would be of interest for the
future similar studies to continue to use both algorithms to
analyze the data to maximize the potential discoveries.
The patients in the current study were treated with
CHOP without Rituximab rather than the current standard
therapy of CHOP with Rituximab; the implication of our
results in the latter setting will require further validation.
Rituximab has an impact on the use of other prognostic
markers such as BCL-2 or BCL-6 [24, 25]. Nevertheless,
the prognostic significance of GCB vs. ABC subtype of
DLBCL remains valid in a recent study by LLMPP con-
sortium using microarray data [26], although the prognostic
significance of GCB vs. non-GCB using IHC remains not
well defined [27]. Our work should prompt the interest of
the investigators to study c-REL expression in their patient
cohort to evaluate the significance of our findings in the
Rituximab era.
In summary, our data suggest that the evaluation of c-
REL nuclear expression combined with GCB and non-GCB
phenotyping by IHC may improve patient risk stratification
in DLBCL. Further studies are needed to substantiate the
clinical significance of our findings.
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